Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...
Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad, reducing their need for clinic visits. New guidance (PDF) from health ...
Medscape UK : Get the latest medical news, drug alerts, expert commentary, clinical guidelines, and practice of medicine coverage for UK healthcare professionals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results